Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 11 - 20 of 44 results.

You searched for : April 2020 to April 2021.

ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society

ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society Download the PDF version of Article January 27, 2021 Tokyo, Munich and Basking Ridge, NJ – (January 27, 2021) –...

ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive A ...

ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer   Download the PDF version of Article January 15, 2021 First HER2 directed...

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment ...

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer January 13, 2021 Interim DESTINY-Lung01 research data from the HER2 overexpressing...

TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metas ...

TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic Alterations Download the PDF version of Article December 14,...

TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docet ...

TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic...

Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with H ...

Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium...

ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Pos ...

ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer Download the PDF version of Article December 10, 2020 Median...

Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS

Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS Download the PDF version of Article November 17, 2020 Longer follow-up research data for ENHERTU® based on...

Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organ ...

Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer Download the PDF version of Article November 12, 2020...

DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER ...

DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy Download the PDF version of...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...